Scheduling Decisions Don’t Just Change the Law. They Change Your Business.
Under the Controlled Substances Act, substances may be added to, removed from, or transferred between schedules through formal administrative rulemaking under 21 U.S.C. § 811. The process involves scientific review by the Secretary of Health and Human Services (HHS), DEA analysis of abuse potential and public health risk, and notice-and-comment rulemaking in which interested parties may submit evidence and argument.
How Scheduling Decisions Affect Your Business
Scheduling decisions carry material consequences for manufacturers, researchers, distributors, pharmacies, prescribers, and healthcare systems across the entire supply chain.
Rescheduling does not eliminate DEA oversight. It changes the specific regulatory controls that apply, including quota applicability, prescribing restrictions, recordkeeping requirements, and security standards, and requires compliance transitions that must be planned before the change takes effect.
A registrant who is not ready for the transition faces immediate compliance exposure on the effective date.
How Jani Law PLLC Can Help
Jani Law PLLC advises registrants and interested stakeholders on scheduling petition strategy, evidentiary submissions, and public comment participation in notice-and-comment rulemaking.
Jani Law PLLC also represents interested parties through the DEA’s administrative hearing process in scheduling and rescheduling proceedings. The evidentiary record and legal arguments developed at the hearing stage can shape the outcome and determine whether a final rule withstands judicial challenge.
Note: The regulatory status of specific controlled substances is subject to change through ongoing administrative proceedings. Consult current DEA and HHS guidance for the most current classification and compliance obligations.